Scientific Sessions


On This Page:

To search a full listing of sessions available at this year’s conference, use the AAIC Interactive Program Guide.


Plenary Sessions

10:30 - 11:15 a.m.

Association Welcome

Session: PL-01-01

11:15 - 11:45 a.m.

Understanding the Earliest Phases of Alzheimer’s Disease

Marilyn Albert
Johns Hopkins University School of Medicine, USA
Theme: Therapeutics
Session: PL-01-02

10:30 - 11 a.m.

Sleep, Brain and Cognition

Ruth M. Benca
University of California, Irvine, USA
Theme: Therapeutics
Session: PL-02-01

11 - 11:30 a.m.

Alzheimer’s Disease Blood-Based Biomarkers and AD Control

SangYun Kim
Seoul National University, South Korea
Theme: Diagnosis and Prognosis
Session: PL-02-02

10:30 - 11 a.m.

Inge Grundke-Iqbal Award for Alzheimer’s Research: Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia

Shane A. Liddelow, Ph.D.
NYU School of Medicine, USA
Theme: Basic and Translational Science
Session: PL-03-01

11 - 11:30 a.m.

The Epidemiology of Diversity and Dementia

Rachel Whitmer
University of California, Davis, USA
Theme: Public Health and Psychosocial
Session: PL-03-02

10:30 - 11 a.m.

Imaging Neurodegeneration With MRI: What Is New?

David Wolk
University of Pennsylvania Memory Center, USA
Theme: Diagnosis and Prognosis
Session: PL-04-01

11 - 11:30 a.m.

The Cellular Phase of Alzheimer’s Disease

Bart De Strooper
University College London, United Kingdom; University of Leuven, Belgium
Theme: Basic and Translational Science
Session: PL-04-02

10:30 - 11 a.m.

Microglia in Neurodegenerative Conditions

Marco Colonna
Washington University in St. Louis, USA
Theme: Basic and Translational Science
Session: PL-05-01

11 - 11:30 a.m.

Precision Medicine, Population Neuroscience and Comprehensive Care: Partners to Develop and Deliver Effective Prevention and Treatments for Dementia

Sudha Seshadri
The University of Texas Health Science Center at San Antonio, USA
Theme: Public Health & Psychosocial
Session: PL-05-02

Symposium Sessions

Sunday, July 14
  • Disparities in Access to Dementia Care and Prevention [S1-01]
    8 - 9:30 a.m.

    Theme: Public Health and Psychosocial



Dementia Prevention Programs in Urban and Regional Aboriginal Communities in Australia [S1-01-01]

Kylie Radford
University of New South Wales, Australia

Health Literacy and Access to Dementia Care [S1-01-02]

Jennifer Lingler
University of Pittsburgh, USA

Improving the Lives of People with Dementia - The OECD Perspective [S1-01-03]

Elina Suzuki
Organization for Economic Co-operation and Development, France

Dementia As Access Barrier in Palliative Care [S1-01-04]

Jenny T. van der Steen
Leiden University Medical Center, Leiden, Netherlands

Sunday, July 14
  • “Rare Variants” And Their Role In Genetic Etiology And Disease [S1-02]
    8 - 9:30 a.m.

    Theme: Basic and Translational Science



Clustering of Rare Variants in Alzheimer Disease and Related Disorders in the Colombian Population: A Genomic Study [S1-02-01]

Ken Kosik
University of California, USA

The Potential Contribution of Rare Variants to Neurodegenerative Brain Dementia [S1-02-02]

Gary Beecham
The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, USA

Whole-Exome Sequencing in 20,197 Persons for Rare Variants in Alzheimer's Disease [S1-02-03]

Richard Mayeux
Columbia University Medical Center, USA

High-Throughput Identification of Noncoding Functional SNPs [S1-02-04]

Gang Li
University of Pittsburgh School of Medicine, USA

Monday, July 15
  • PET and CSF Markers of Neuroinflammation [S2-01]
    8 - 9:30 a.m.

    Theme: Diagnosis and Prognosis



PET Markers of Microglia [S2-01-01]

Robert Innis
National Institute of Mental Health, USA

PET Markers of Astrocytes [S2-01-02]

Elena Rodriguez-Vieitez
Karolinska Institute, Sweden

Neuroinflammation: CSF Perspective [S2-01-03]

Shorena Janelidze
Lund University, Sweden

Fluid Biomarkers of Neuroinflammation [S2-01-04]

Charlotte Teunissen
VU University Medical Center, Netherlands

Monday, July 15
  • Precision Medicine [S2-02]
    8 - 9:30 a.m.

    Theme: Therapeutics



Precision Medicine Model for Targeted NSAID Therapy in AD [S2-02-01]

Sid O'Bryant
University of North Texas Health Science Center, USA

PPAR-Gamma [S2-02-02]

Michael Heneka
German Center for Neurodegenerative Diseases (DZNE), Germany

Insulin-Resistant Sub-Typing [S2-02-03]

Suzanne Craft
Wake Forest School of Medicine, USA

Subtyping of Clinical Subjects through Exosome Analyses [S2-02-04]

Dimitrios Kapogiannis
National Institute on Aging/National Institutes of Health (NIA/NIH), USA

Tuesday, July 16
  • Overlapping AD Pathologies and their Influence on Disease Phenotypes [S3-01]
    8 - 9:30 a.m.

    Theme: Diagnosis and Prognosis



Alzheimer’s and Vascular Disease: A Pathobiological Perspective [S3-01-01]

Costantino Iadecola
Weill Cornell Medicine, USA

Alzheimer’s Disease and Subcortical Vascular Cognitive Impairment (SVCI): Biomarker Perspective [S3-01-02]

Duk Na
Samsung Medical Center; Sungkyunkwan University School of Medicine, Korea, Republic of Korea (South)

Alzheimer’s and Lewy Body Disease: Pathologic Perspective [S3-01-03]

David Irwin
University of Pennsylvania, USA

Alzheimer’s and Lewy Body Disease: Biomarker Perspective [S3-01-04]

Evelien Lemstra
Amsterdam University Medical Centers, Netherlands

Tuesday, July 16
  • Responder Analyses Leading to Hypothesis Generation for Prospective Study Designs [S3-02]
    8 - 9:30 a.m.

    Theme: Therapeutics



Statistical Challenges With Responder Analysis in Exploratory Settings [S3-02-01]

Suzanne Hendrix
Pentara Corporation, USA

Multi-Crossover Randomized Control Design Approaches Based on Analyses of Responder/Non-Responder Outcomes [S3-02-02]

Steven Arnold Massachusetts General Hospital, USA; Harvard Medical School, USA
To be announced.

Statistical Considerations for Efficient Designs within a Platform Trial Approach [S3-02-03]

Karen Messer
University of California San Diego, USA

Determining Whether Identification of a Responder Sub-Group Is Truly Hypothesis Generating [S3-02-04]

Eric Siemers
Siemers Integration LLC, USA

Wednesday, July 17
  • National Dementia Registries: Quality Control and Recruitment of Research Participants [S4-01]
    8 - 9:30 a.m.

    Theme: Public Health and Psychosocial



Identifying Elders at Risk for Cognitive Decline Using the Brain Health Registry (BHR) [S4-01-01]

Michael Weiner
University of California, San Francisco, USA

The Dutch Brain Health Registry for Recruitment of Research Participants [S4-01-02]

Marissa Zwan
VU University Medical Center, Netherlands

Swedish Clinical Quality Registry for Dementia [S4-01-03]

Dorota Religa
Karolinska Institute, Sweden

The Australian Dementia Network (ADNet) Clinical Quality Registry [S4-01-04]

Stephanie Ward
Monash University, Australia

Thursday, July 18
  • Delirium in Dementia: A Translational Aspect [S5-01]
    8:30 - 10 a.m.

    Theme: Basic and Translational Science



Description and Impact of Delirium on Dementia [S5-01-01]

Daniel Davis
University College London, United Kingdom

Biomarkers in Delirium [S5-01-02]

Gideon Caplan
University of New South Wales, Australia

Neurobiology of Delirium and Its Intersection with Dementia: Insights from Animal Models [S5-01-03]

Colm Cunningham
Trinity College Dublin, Ireland

Systemic Inflammation Signaling to the Brain [S5-01-04]

Roosmarijn Vandenbroucke
Ghent University, Belgium

Thursday, July 18
  • Focused Topic Session: Review of Developments in Disease Modifying Strategies for Alzheimer’s Disease: A Focus on Anti-Amyloid Strategies [FTS5-01]
    8:30 - 10 a.m.



Immunotherapy in Alzheimer Disease: Mechanisms of Monoclonal Antibodies in Development [FTS5-01-01]

Christopher van Dyck
Yale School of Medicine, USA

Correlating Cognitive Outcomes with Patient Specific Biomarkers in Alzheimer’s Disease [FTS5-01-02]

Jose Luis Molinuevo
ICN Hospital Clinic i Universitari, Spain

A Pharmacokinetic / Pharmacodynamic Evaluation of Imaging Biomarkers of Alzheimer's Disease [FTS5-01-03]

Tammie Benzinger
Knight Alzheimer's Disease Research Center, USA

The Amyloid Hypothesis: Latest Update in the Context of Recent Trial Evidence [FTS5-01-04]

Reisa Sperling
Brigham and Women's Hospital, USA

Panel Discussion [FTS5-01-05]

Presentation Speakers

Join the Conversation #AAIC19






> 1200px
> 992px
> 768px
< 767px